Marc Hafner

Scopus Author ID Loop profile ORCID

Publication Activity (10 Years)

Years Active: 2016-2024
Publications (10 Years): 18

Top Venues

NPJ breast cancer

Nature communications

Nature cancer

Scientific data

Genentech

École Polytechnique Fédérale de Lausanne (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Genentech Nov 13 2017

United States

Scientist :: Bioinformatics and Computational Biology

Harvard Medical School Jan 15 2012 - Nov 12 2017

United States

Postdoctoral fellow :: Systems Biology

Swiss Federal Institute of Technology in Zurich Mar 01 2011 - Sep 01 2011

Switzerland

Postdoctoral fellow :: Information Technology and Electrical Engineering

Education History

École Polytechnique Fédérale de Lausanne May 01 2007 - Feb 28 2011

Switzerland

PHD :: Informatics and Communication

Publications

Nayan Chaudhary, Alejandro M Chibly, Ann Collier, Jorge Martinalbo, Pablo Perez-Moreno, Heather M Moore, Patricia Luhn, Ciara Metcalfe, Marc Hafner
CDK4/6i-treated HR+/HER2- breast cancer tumors show higher ESR1 mutation prevalence and more altered genomic landscape. NPJ breast cancer 10 (1) (2024)
Nayan Chaudhary, Alejandro M Chibly, Ann Collier, Jorge Martinalbo, Pablo Perez-Moreno, Heather M Moore, Patricia Luhn, Ciara Metcalfe, Marc Hafner
CDK4/6i-treated HR+/HER2- breast cancer tumors show higher ESR1 mutation prevalence and more altered genomic landscape. NPJ breast cancer 10 (1) (2024)
Nayan Chaudhary, Alejandro M Chibly, Ann Collier, Jorge Martinalbo, Pablo Perez-Moreno, Heather M Moore, Patricia Luhn, Ciara Metcalfe, Marc Hafner
CDK4/6i-treated HR+/HER2- breast cancer tumors show higher ESR1 mutation prevalence and more altered genomic landscape. NPJ breast cancer 10 (1) (2024)
Nayan Chaudhary, Alejandro M Chibly, Ann Collier, Jorge Martinalbo, Pablo Perez-Moreno, Heather M Moore, Patricia Luhn, Ciara Metcalfe, Marc Hafner
CDK4/6i-treated HR+/HER2- breast cancer tumors show higher ESR1 mutation prevalence and more altered genomic landscape. NPJ breast cancer 10 (1) (2024)
Marian Kalocsay, Matthew J Berberich, Robert A Everley, Maulik K Nariya, Mirra Chung, Benjamin L Gaudio, Chiara Victor, Gary A Bradshaw, Robyn J Eisert, Marc Hafner, Peter Karl Sorger, Caitlin E Mills, Kartik Subramanian
Proteomic profiling across breast cancer cell lines and models. Scientific data 10 (1) (2023)
Thijs J Hagenbeek, Jason R Zbieg, Marc Hafner, Rana Mroue, Jennifer A Lacap, Nicole M Sodir, Cameron L Noland, Shervin Afghani, Ayush Kishore, Kamakoti P Bhat, Xiaosai Yao, Stephen Schmidt, Saundra Clausen, Micah Steffek, Wendy Lee, Paul Beroza, Scott Martin, Eva Lin, Rina Fong, Paola Di Lello, Marta H Kubala, Michelle N-Y Yang, Jeffrey T Lau, Emily Chan, Alfonso Arrazate, Le An, Elizabeth Levy, Maria N Lorenzo, Ho-June Lee, Trang H Pham, Zora Modrusan, Richard Zang, Yi-Chen Chen, Michal Kabza, Musaddeque Ahmed, Jason Li, Matthew T Chang, Danilo Maddalo, Marie Evangelista, Xin Ye, James J Crawford, Anwesha Dey
An allosteric pan-TEAD inhibitor blocks oncogenic YAP/TAZ signaling and overcomes KRAS G12C inhibitor resistance. Nature cancer (2023)
Caitlin E Mills, Kartik Subramanian, Marc Hafner, Mario Niepel, Luca Gerosa, Mirra Chung, Chiara Victor, Benjamin Gaudio, Clarence Yapp, Ajit J Nirmal, Nicholas Clark, Peter Karl Sorger
Multiplexed and reproducible high content screening of live and fixed cells using Dye Drop. Nature communications 13 (1) (2022)
Rocky Diegmiller, Laurent Salphati, Bruno Alicke, Timothy R Wilson, Thomas J Stout, Marc Hafner
Growth-rate model predicts in vivo tumor response from in vitro data. CPT: pharmacometrics & systems pharmacology 11 (9) (2022)
Jackson Liang, Ellen Rei Ingalla, Xiaosai Yao, Bu-Er Wang, Lisa Tai, Jennifer M Giltnane, Yuxin Liang, Anneleen Daemen, Heather M Moore, Junko Aimi, Ching-Wei Chang, Mary R Gates, Jennifer Eng-Wong, Lucinda Tam, Natasha Bacarro, Merone Roose-Girma, Meritxell Bellet-Ezquerra, Marc Hafner, Ciara Metcalfe
Giredestrant reverses progesterone hypersensitivity driven by estrogen receptor mutations in breast cancer. Science translational medicine 14 (663) (2022)
Ariel Pribluda, Anneleen Daemen, Anthony Nelson Lima, Xi Wang, Marc Hafner, Chungkee Poon, Zora Modrusan, Anand Kumar Katakam, Oded Foreman, Jefferey Eastham, Jefferey Hung, Benjamin Haley, Julia T Garcia, Erica L Jackson, Melissa R Junttila
EHMT2 methyltransferase governs cell identity in the lung and is required for KRAS G12D tumor development and propagation. eLife 11 (2022)
Kyung W Song, Kyle A Edgar, Emily J Hanan, Marc Hafner, Jason Oeh, Mark Merchant, Deepak Sampath, Michelle A Nannini, Rebecca Hong, Lilian Phu, William F Forrest, Eric Stawiski, Stephen Schmidt, Nicholas Endres, Jane Guan, Jeffrey J Wallin, Jonathan Cheong, Emile G Plise, Gail D Lewis Phillips, Laurent Salphati, Timothy P Heffron, Alan G Olivero, Shiva Malek, Steven T Staben, Donald S Kirkpatrick, Anwesha Dey, Lori S Friedman
RTK-dependent inducible degradation of mutant PI3Kα drives GDC-0077 (Inavolisib) efficacy. Cancer discovery (2021)
Nikta Feizi, Sisira Kadambat Nair, Petr Smirnov, Gangesh Beri, Christopher Eeles, Parinaz Nasr Esfahani, Minoru Nakano, Denis Tkachuk, Anthony Mammoliti, Evgeniya Gorobets, Arvind Singh Mer, Eva Lin, Yihong Yu, Scott Martin, Marc Hafner, Benjamin Haibe-Kains
PharmacoDB 2.0: improving scalability and transparency of in vitro pharmacogenomics analysis. Nucleic acids research (2021)
Anthony Mammoliti, Petr Smirnov, Minoru Nakano, Zhaleh Safikhani, Christopher Eeles, Heewon Seo, Sisira Kadambat Nair, Arvind S Mer, Ian Smith, Chantal Ho, Gangesh Beri, Rebecca Kusko, null null, Eva Lin, Yihong Yu, Scott Martin, Marc Hafner, Benjamin Haibe-Kains
Orchestrating and sharing large multimodal data for transparent and reproducible research. Nature communications 12 (1) (2021)
Jianzhu Ma, Samson H Fong, Yunan Luo, Christopher J Bakkenist, John Paul Shen, Soufiane Mourragui, Lodewyk F A Wessels, Marc Hafner, Roded Sharan, Jian Peng, Trey Ideker
Few-shot learning creates predictive models of drug response that translate from high-throughput screens to individual patients. Nature cancer 2 (2) (2021)
Marc Hafner, Mario Niepel, Peter K Sorger
Alternative drug sensitivity metrics improve preclinical cancer pharmacogenomics. Nature biotechnology 35 (6) (2018)
Mario Niepel, Marc Hafner, Qiaonan Duan, Zichen Wang, Evan O Paull, Mirra Chung, Xiaodong Lu, Joshua M Stuart, Todd R Golub, Aravind Subramanian, Avi Ma'ayan, Peter Karl Sorger
Common and cell-type specific responses to anti-cancer drugs revealed by high throughput transcript profiling. Nature communications 8 (1) (2017)
Marc Hafner, Laura M Heiser, Elizabeth H Williams, Mario Niepel, Nicholas J Wang, James E Korkola, Joe W Gray, Peter K Sorger
Quantification of sensitivity and resistance of breast cancer cell lines to anti-cancer drugs using GR metrics. Scientific data 4 (2017)
Marc Hafner, Mario Niepel, Mirra Chung, Peter K Sorger
Growth rate inhibition metrics correct for confounders in measuring sensitivity to cancer drugs. Nature methods 13 (6) (2016)

Marc Hafner.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Marc Hafner